



PCT/PTO 20 DEC 2004  
PCT/GB 2003 / 0 0 2 6 4 5



INVESTOR IN PEOPLE

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 17 JUL 2003


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

*D. Mahoney*

10 JUL 2003

BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977  
(Rule 16)



0214406.1  
24JUN02 E727870-1 000060  
P01/7700 010-0214406.1  
**1/77**

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

21 JUN 2002

1. Your reference **SMK/LP6054712**

2. Patent application number  
(The Patent Office will fill in this part) **0214406.1**

3. Full name, address and postcode of the or of each applicant (underline all surnames)  
Patents ADP number (if you know it)

Plant Bioscience Limited  
Norwich Research Park  
Colney Lane  
Norwich  
Norfolk NR4 7UH  
UNITED KINGDOM

If the applicant is a corporate body, give the country/state of its incorporation

GB

7489982001

4. Title of the invention **Plant-Derived Transferase Genes**

5. Name of your agent (if you have one) **MEWBURN ELLIS**

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

YORK HOUSE  
23 KINGSWAY  
LONDON  
WC2B 6HP

Patents ADP number (if you know it)

109006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
--	---------	--	-------------------------------------

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)
---	-------------------------------	-------------------------------------

8. Is a statement of inventorship and of right to grant of a patent required in support of this request?

(Answer "Yes" if:

a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

YES

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 42

Claim(s)

Abstract

Drawing(s) 9 *1 a 4m*

10. If you are also filing any of the following, state how many against each item

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(*Please specify*)

11.

I/We request the grant of a patent on the basis of this application.

Signature

*MEWBURN ELLIS*

Date

21 June 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

SIMON M KREMER

020 7240 4405

**Warning**

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

**Notes**

- a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.*
- b) *Write your answers in capital letters using black ink or you may type them.*
- c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- d) *If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- e) *Once you have filled in the form you must remember to sign and date it.*
- f) *For details of the fee and ways to pay please contact the Patent Office.*

PLANT-DERIVED TRANSFERASE GENESTECHNICAL FIELD

5 The present invention relates to methods and materials for controlling chlorogenic acid synthesis based on manipulation of hydroxycinnamoyl-CoA quinate hydroxycinnamoyl transferase (HQT) genes.

10 BACKGROUND ART

The plant phenylpropanoid pathway is responsible for the synthesis of a wide variety of secondary metabolic compounds, including lignins, salicylates, coumarins, hydroxycinnamic amides, flavonoid  
15 phytoalexins, pigments, UV light protectants and antioxidants (DIXON and PAIVA, 1995). Phenylpropanoids have a range of important functions in plants, such as structural components (lignin), protectants against biotic and abiotic stresses (antipathogenic phytoalexins, antioxidants and UV-absorbing compounds), pigments  
20 (anthocyanins) and signalling molecules (flavonoid nodulation factors; STRACK, 1997). In addition to their role in structure and protection of the plants, the compounds of the phenylpropanoid pathway also have an important effect on plant qualities, such as texture, flavour, colour and processing characteristics (MACHEIX et  
25 al., 1991).

Chlorogenic acid, an ester of quinic and caffeic acid (STOECKIGT and ZENK, 1974), is a major compound of the phenylpropanoid pathway in Coffea and Solanaceous species such as tobacco, tomato and sweet  
30 potato. The levels of chlorogenic acid are constitutively high in some species (Coffea), while in others the biosynthesis of chlorogenic acid can be induced by a variety of stimuli, such as high light (KUEHNLE et al., 1987, GRACE et al., 1998), UV radiation (DEL MORAL, 1972), wounding (RHODES and WOOLVERTON, 1978), and fungal  
35 elicitors (YAO et al., 1995).

The fact that chlorogenic acid is one of the initial products formed during the transcriptional activation of the phenylpropanoid pathway by pathogen infection and abiotic stress, led to the assumption that chlorogenic acid acts as a carbon reservoir. The mobilization of this pool to form downstream phenylpropanoid products such as lignins, phytoalexins and cell wall cross-linking agents would enable the plants to respond immediately to pathogen attack (YAO et al., 1995, DIAZ et al., 1997).

Recent studies proposed another potential function of chlorogenic acid in plants - as an antioxidant. Environmental stresses such as high light, UV light, low temperature and pathogen infection can all lead to an increase of reactive oxygen species in plants. To avoid lethal damage caused by these oxidative species, plants have developed a complex antioxidant system. In addition to the well-characterised system which includes enzymes such as superoxide dismutase or ascorbate peroxidase, a few studies have analysed the role of phenolic metabolites in scavenging reactive oxygen species (GRACE and LOGAN, 2000). Chlorogenic acid has been shown to have antioxidant activity (CASTELLUCCIO et al., 1995, KONO et al., 1997). Polyphenols such as chlorogenic acid are ideal for free-radical scavenging activities due to the hydrogen-donating activity of their catechol groups and have been shown to be more effective antioxidants in vitro than vitamins E and C (RICE-EVANS et al., 1997).

Free radicals and other reactive species are considered to be important factors in the development of cancer and cardiovascular diseases. Due to their antioxidant capacity the interest in food polyphenolics such as chlorogenic acid has increased. Food phenolics are thought to provide beneficial implications in human health, e.g. in the treatment and prevention of cancer (BRAVO, 1998, RICE-EVANS et al., 1997).

Two different pathways have been proposed for the biosynthesis of chlorogenic acid. In sweet potato the enzyme hydroxycinnamoyl-D-glucose quinate hydroxycinnamoyl transferase has been isolated

(VILLEGAS and KOJIMA, 1986). This catalyses the transfer of the caffoyl moiety of caffeoyl-D-glucose to quinic acid.

An alternative pathway has been proposed on the basis of  
5 chlorogenic acid biosynthesis in tobacco cell suspension cultures  
initially described by STOECKIGT and ZENK (1974). This involves  
transesterification between caffeoyl-CoA thiolesters and quinic  
acid. The enzyme catalysing this reaction, hydroxycinnamoyl-CoA  
quininate hydroxycinnamoyl transferase (HQT) has not yet been  
10 isolated.

Recently, the isolation of a 3-hydroxylase from Arabidopsis, which  
has been shown to catalyze the formation of chlorogenic acid by  
hydroxylation of coumaroyl quinic acid in vitro, led to the  
15 consideration that plants may also be able to synthesize  
chlorogenic acid by hydroxylation (SCHOCH et al., 2001).

Although HQT has been partially purified from various plant  
species, particularly in Solanaceae (RHODES and WOOLTON, 1976,  
20 RHODES et al., 1979, ULBRICH and ZENK, 1979, LOFTY et al., 1992, LOFTY  
et al., 1994), the gene has not been isolated.

Indeed, to date 116 transferases have been identified in plants  
(examples include anthranilate N-hydroxycinnamoyl/benzoyl  
25 transferase, that catalyses the first committed reaction of  
phytoalexin biosynthesis, deacetylvindoline 4-O-acetyltransferase  
and trichothecene 3-O-acetyltransferase). Nevertheless, apart from  
the DFGWG sequence motif, there are only few conserved amino acids  
within the transferase family. Even within the subgroup of  
30 anthranilate N-hydroxycinnamoyl/benzoyl transferase the amino acid  
sequences differ so much that the enzymes from Arabidopsis and  
clove pink are not closely related (Figure 4). This suggests that  
it is very difficult to correlate the function of a transferase  
with the sequence information provided. Hence, cloning a  
35 transferase of known function is far from straightforward.

In solving the problem of providing the HQT gene, the inventors originally thought the tobacco hypersensitive response protein 201 would be a good candidate for HQT because of its expression pattern during hypersensitive response after pathogen attack. Hsr201 is a member of the transferase family and shows less homology to known anthranilate transferase, which indicates a putative new function in tobacco. However, the recombinant protein expressed in *E. coli* showed no HQT enzyme activity (Figure 5).

The isolation and characterization of the gene and enzyme HQT that catalyses the synthesis of chlorogenic acid, the major antioxidant in higher plants, may contribute *inter alia* to improvements in the antioxidant content of food. It could further be used to modify *inter alia*, this and other traits in plants.

#### DISCLOSURE OF THE INVENTION

The inventors have succeeded in cloning HQT genes from plants. This is the first time a gene known to encode an HQT has been cloned.

In order to provide the HQT genes, briefly, the inventors purified HQT from tobacco leaves by using anion exchange and hydrophobic interaction chromatography (Figure 1). As noted above, no isolated HQT had previously been published. The purification procedure gave a pure protein with HQT enzyme activity. The reaction product of the enzyme assay was identified by HPLC analysis as chlorogenic acid, the product of the esterification of quinic acid with caffeoyl-CoA.

Two partial amino acid sequences of the purified protein, obtained from Q-TOF analysis were found to match with a hydroxycinnamoyl-benzoyl transferase from sweet potato and the translation products of tobacco and tomato EST clones. By using overlapping tomato EST clones a full-length cDNA was assembled (see Figure 2).

Using the sequence of the EST clones the full-length cDNA clones of HQT from tobacco and tomato were isolated by using RT-PCR. The two related cDNAs encode 430 amino acids (tomHQT, calculated mass 47,960 D) and 436 amino acids (tobHQT, calculated mass of 48,390 D). The amino acid sequences show 90% homology to each other and 81-83% homology to the N-hydroxycinnamoyl/benzoyl transferase from sweet potato (accession number AB035183). Although the activity and substrate specificity of the sweet potato protein has apparently not been characterised, the classification of the protein as an N-hydroxycinnamoyl/benzoyl transferase has been made according to sequence homologies to other members of the transferase family. In the light of the disclosure herein, it appears this enzyme may also have HQT activity.

The encoded protein sequences of both cDNA clones contain the DFGWG sequence motif that is characteristic of transferases from plants and may therefore form part of the active site.

To confirm the identity of proteins as HQT the enzyme activity was analysed after expressing the cDNA from tomato in *E. coli*. As shown in Figure 5 the recombinant expressed protein showed HQT enzyme activity in contrast to the expression of hsr201 where no enzyme activity was detected.

Increased HQT enzyme activity was also detected in leaves of *Nicotiana benthamiana* plants expressing high levels of tomato and tobacco HQT under the control of the 35S promoter (Figure 6). This increase in enzyme activity leads to a 2-fold higher amount of chlorogenic acid in vivo in plants indicating that the synthesis of chlorogenic acid might not be as strictly regulated as previously assumed and that the substrates are not limiting.

In various aspects of the invention the HQT gene, or its variants, may be employed in the regulation of chlorogenic acid synthesis in a plant. Regulation of chlorogenic acid synthesis may be used *inter alia* to alter the flavour, palatability, texture, nutritional value or antioxidant properties of the plant.



According to an aspect of the present invention there is provided an isolated nucleic acid molecule encoding a polypeptide which has HQT activity (i.e. an HQT).

5

As described above, HQT catalyses the production of chlorogenic acid via transfer of the caffeoyl moiety of caffeoyl-CoA to quinic acid. Such activity can be assessed, for example, using the assay described in Example 2. Briefly, the assay uses caffeoyl CoA and quinic acid as substrates, and the rate of conversion of caffeoyl CoA to chlorogenic acid is determined by spectrophotometry.

10

Nucleic acid according to the present invention may include cDNA, RNA, genomic DNA and modified nucleic acids or nucleic acid analogs (e.g. peptide nucleic acid). Where a DNA sequence is specified, e.g. with reference to a figure, unless context requires otherwise the RNA equivalent, with U substituted for T where it occurs, is encompassed.

15

Likewise, DNA is generally found in double-stranded form, and the complementary strand of such DNA sequences is also included in the ambit of the invention. A nucleic acid is "the complement" of another nucleic acid to which it is complementary. 'Complementary to' means that the sequence is capable of base pairing with the coding sequence whereby A is the complement of T (and U); G is the complement of C; and may be of equal length to, or of a portion of, said DNA sequence.

20

25

Nucleic acid molecules according to the present invention may be provided in isolated and/or purified from their natural environment, in substantially pure or homogeneous form, or free or substantially free of other nucleic acids of the species of origin. Where used herein, the term 'isolated' encompasses all of these possibilities. The nucleic acid molecules may be wholly or partially synthetic. In particular they may be recombinant in that nucleic acid sequences which are not found together in nature (do not run contiguously) have been ligated or otherwise combined

30

35

artificially. Alternatively they may have been synthesised directly e.g. using an automated synthesiser.

Most preferably the nucleic acid is derived from tobacco or tomato.

5 Thus included in this aspect of the invention, there are also provided nucleic acids encoding the polypeptides of Fig 3. Such nucleic acids may have the sequences of Fig 7, or may consist or comprise the coding portion thereof (such as that underlined in Figure 7b).

10 In this aspect of the present invention there are also provided nucleic acids which are variants of the said sequences. A variant nucleic acid molecule shares homology with, or is identical to, all or part of the coding sequence discussed above. Generally variants  
15 may encode, or be used to isolate or amplify nucleic acids which encode, polypeptides which have HQT activity as described above. However, variants which do not encode polypeptides having HQT activity are also provided, eg. for use in probing or silencing. Variants of the present invention can be artificial nucleic acids,  
20 which can be prepared by the skilled person in the light of the present disclosure. Alternatively they may be novel, naturally occurring, nucleic acids, isolatable using the sequences of the present invention.

25 Sequence variants which occur naturally may include HQT alleles (which typically include polymorphisms or mutations at one or more bases) or pseudoalleles (which may occur at closely linked loci to the HQT gene). Also included within the scope of the present invention are isogenes, or other genes homologous to the HRT  
30 sequences of the invention and belonging to the same family as the HQT gene. Although these may occur at different genomic loci to the HQT gene, they typically share conserved regions with it.

Artificial variants (derivatives) may be prepared by those skilled  
35 in the art, for instance by site directed or random mutagenesis, or by direct synthesis. Preferably the variant nucleic acid is generated either directly or indirectly (e.g. via one or more

amplification or replication steps) from an original nucleic acid having all or part of the sequence shown in Figure 7.

Thus a variant may be a distinctive part or fragment (however produced) corresponding to a portion of the sequence provided. The fragments may encode particular functional parts of the polypeptide. Alternatively, the fragments may have utility in probing for, or amplifying, the sequence provided or closely related ones. Suitable lengths of fragment, and conditions, for such processes are discussed in more detail below.

Also included are nucleic acids corresponding to those above, but which have been extended at the 3' or 5' terminus.

The term 'variant' nucleic acid as used herein encompasses all of these possibilities. When used in the context of the present invention with regard to polypeptides or proteins, 'variant' indicates the encoded expression product of the variant nucleic acid.

Some of the aspects of the present invention relating to variants will now be discussed in more detail.

Similarity or homology (the terms are used interchangeably) or identity may be as defined and determined by the TBLASTN program, of Altschul et al. (1990) J. Mol. Biol. 215: 403-10, or BestFit, which is part of the Wisconsin Package, Version 8, September 1994, (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA, Wisconsin 53711). Preferably sequence comparisons are made using MultAlin (see Corpet, 1988, Nucleic Acids Research 16 10881-10890). Default parameters are preferably set as follows:

Gap value (penalty for the first residue in a gap): -12

Gap length weight (penalty for additional residues in a gap): -2

Alternatively, sequence comparisons may be made using FASTA and FASTP (see Pearson & Lipman, 1988. Methods in Enzymology 183: 63-98). Parameters may be set, using the default matrix, as follows:

- 5 Gapopen (penalty for the first residue in a gap): -12 for proteins  
/ -16 for DNA  
Gapext (penalty for additional residues in a gap): -2 for proteins  
/ -4 for DNA  
KTUP word length: 2 for proteins / 6 for DNA.

10 Homology may be at the nucleotide sequence and/or encoded amino acid sequence level. Preferably, the nucleic acid and/or amino acid sequence shares at least about 90%, 95%, 96%, 97%, 98% or 99% homology or identity.

15 Homology may be over the full-length of the relevant sequence shown herein, or may be over a part of it, preferably over a contiguous sequence of about or greater than about 20, 25, 30, 33, 40, 50, 67, 133, 167, 200, 233, 267, 300, 333, 400 or more amino acids or  
20 codons, compared with Fig 3 respectively.

Thus a variant polypeptide in accordance with the present invention may include within either of the sequences shown in Fig 3, a single amino acid or 2, 3, 4, 5, 6, 7, 8, or 9 changes, about 10, 15, 20,  
25 30, 40 or 50 changes, or greater than about 50, 60, 70, 80 or 90 changes. In addition to one or more changes within the amino acid sequence shown, a variant polypeptide may include additional amino acids at the C-terminus and/or N-terminus. Naturally, changes to the nucleic acid which make no difference to the encoded  
30 polypeptide (i.e. 'degeneratively equivalent') are included.

The activity of functional variant polypeptides may be assessed by transformation into a host capable of expressing the nucleic acid of the invention. Methodology for such transformation is described  
35 in more detail below.

In a further aspect of the invention there is disclosed a method of producing a derivative nucleic acid comprising the step of modifying any of the sequences disclosed above, particularly the coding sequence of Fig 7.

5 Alternatively changes to a sequence may produce a derivative by way of one or more of addition, insertion, deletion or substitution of one or more nucleotides in the nucleic acid, leading to the addition, insertion, deletion or substitution of one or more amino  
10 acids in the encoded polypeptide.

Such changes may modify sites which are required for post translation modification such as cleavage sites in the encoded polypeptide; motifs in the encoded polypeptide for glycosylation,  
15 lipoylation etc. Leader or other targeting sequences (e.g. membrane or golgi locating sequences) may be added to the expressed protein to determine its location following expression.

Other desirable mutation may be random or site directed mutagenesis  
20 in order to alter the activity (e.g. specificity) or stability of the encoded polypeptide. Changes may be by way of conservative variation, i.e. substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for  
25 lysine, glutamic for aspartic acid, or glutamine for asparagine. As is well known to those skilled in the art, altering the primary structure of a polypeptide by a conservative substitution may not significantly alter the activity of that peptide because the side-chain of the amino acid which is inserted into the sequence  
30 may be able to form similar bonds and contacts as the side chain of the amino acid which has been substituted out. This may be so even when the substitution is in a region which is critical in determining the conformation of the peptide. Also included are variants having non-conservative substitutions.

35

As is well known to those skilled in the art, substitutions to regions of a peptide which are not critical in determining its

conformation may not greatly affect its activity because they may not greatly alter the peptide's three dimensional structure. In regions which are critical in determining the peptides conformation or activity such changes may confer advantageous properties on the polypeptide. Indeed, changes such as those described above may confer slightly advantageous properties on the peptide e.g. altered stability or specificity. It may be preferred to retain the putative active site motif DFGWG (amino acid residues 382-386 of the tobacco HQT nucleotide sequence of Figure 3)

10

In a further aspect of the present invention there is provided a method of identifying and/or cloning a nucleic acid variant from a plant which method employs an HQT sequence as described herein.

15 For instance, nucleotide sequence information provided herein may be used in a data-base (e.g. of ESTs, or STSs) search to find homologous sequences, and expression products of which can be tested for activity as described below in Example 2.

20 Nucleotide sequence information provided herein may be used to design probes and primers for probing or amplification of HQT or variants thereof. An oligonucleotide for use in probing or PCR may be about 32 or fewer nucleotides in length (e.g. 16, 18, 21 or 24). Generally specific primers are upwards of 14 nucleotides in length.

25 For optimum specificity, primers of 16-32 nucleotides in length may be preferred. Those skilled in the art are well versed in the design of primers for use processes such as PCR.

Preferred primers which can be used include any of those shown in

30 the Examples below as being suitable for amplifying HQT sequences.

If required, probing can be done with entire restriction fragments of the cDNA sequences disclosed herein, or the full-length cDNAs themselves. Fragments may be used e.g. the sequence employed may be

35 about 100 nucleotides or more, about 200 nucleotides or more, about 300 nucleotides or more, or about 400 nucleotides or more, in each

case the sequence may be a contiguous sequence selected from those nucleic acids disclosed herein.

Naturally sequences may be based on either Fig 7, or the complement thereof. Small variations may be introduced into the sequence to produce 'consensus' or 'degenerate' primers if required.

Such probes and primers form one aspect of the present invention.

Probing may employ the standard Southern blotting technique. For instance DNA may be extracted from cells and digested with different restriction enzymes. Restriction fragments may then be separated by electrophoresis on an agarose gel, before denaturation and transfer to a nitrocellulose filter. Labelled probe may be hybridised to the DNA fragments on the filter and binding determined. DNA for probing may be prepared from RNA preparations from cells. Probing may optionally be done by means of so-called 'nucleic acid chips' (see Marshall & Hodgson (1998) Nature Biotechnology 16: 27-31, for a review).

In one aspect, there is provided a method of obtaining an HQT variant nucleic acid molecule which comprises:

(a) providing a preparation of nucleic acid from a cell, e.g. from plant cells,

(b) providing a nucleic acid molecule which is a nucleic acid of the invention or probe or primer therefor,

(c) contacting nucleic acid in said preparation with said probe or primer under conditions for hybridisation, and,

(d) identifying said nucleic acid variant if present by its hybridisation with said nucleic acid molecule.

Test nucleic acid may be provided from a cell as genomic DNA, cDNA or RNA, or a mixture of any of these, preferably as a library in a

suitable vector. If genomic DNA is used the probe may be used to identify untranscribed regions of the gene (e.g. promoters etc).

Binding of a probe to target nucleic acid (e.g. DNA) may be measured using any of a variety of techniques at the disposal of those skilled in the art. For instance, probes may be radioactively, fluorescently or enzymatically labelled. Other methods not employing labelling of probe include amplification using PCR (see below), RNase cleavage and allele specific oligonucleotide probing. The identification of successful hybridisation is followed by isolation of the nucleic acid which has hybridised, which may involve one or more steps of PCR or amplification of a vector in a suitable host.

Preliminary experiments may be performed by hybridising under low stringency conditions. For probing, preferred conditions are those which are stringent enough for there to be a simple pattern with a small number of hybridisations identified as positive which can be investigated further.

For example, hybridizations may be performed, according to the method of Sambrook et al. (below) using a hybridization solution comprising: 5X SSC (wherein 'SSC' = 0.15 M sodium chloride; 0.15 M sodium citrate; pH 7), 5X Denhardt's reagent, 0.5-1.0% SDS, 100 µg/ml denatured, fragmented salmon sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide. Hybridization is carried out at 37-42°C for at least six hours. Following hybridization, filters are washed as follows: (1) 5 minutes at room temperature in 2X SSC and 1% SDS; (2) 15 minutes at room temperature in 2X SSC and 0.1% SDS; (3) 30 minutes - 1 hour at 37°C in 1X SSC and 1% SDS; (4) 2 hours at 42-65°C in 1X SSC and 1% SDS, changing the solution every 30 minutes.

One common formula for calculating the stringency conditions required to achieve hybridization between nucleic acid molecules of a specified sequence homology is (Sambrook et al., 1989):  $T_m =$



81.5°C + 16.6Log [Na+] + 0.41 (% G+C) - 0.63 (% formamide) -  
600/#bp in duplex

As an illustration of the above formula, using [Na+] = [0.368] and  
5 50-% formamide, with GC content of 42% and an average probe size of  
200 bases, the  $T_m$  is 57°C. The  $T_m$  of a DNA duplex decreases by 1 -  
1.5°C with every 1% decrease in homology. Thus, targets with  
greater than about 75% sequence identity would be observed using a  
hybridization temperature of 42°C. Such a sequence would be  
10 considered substantially homologous to the nucleic acid sequence of  
the present invention.

It is well known in the art to increase stringency of hybridisation  
gradually until only a few positive clones remain. For detection  
15 of sequences that are greater than about 90% identical, suitable  
conditions include hybridization overnight at 65 °C in 0.25M  
Na<sub>2</sub>HPO<sub>4</sub>, pH 7.2, 6.5% SDS, 10% dextran sulfate and a final wash at  
60 °C in 0.1X SSC, 0.1% SDS.

20 An alternative, which may be particularly appropriate with plant  
nucleic acid preparations, is a solution of 5x SSPE (final 0.9 M  
NaCl, 0.05M sodium phosphate, 0.005M EDTA pH 7.7), 5X Denhardt's  
solution, 0.5% SDS, at 65 °C overnight, (for high stringency, highly  
similar sequences). Washes in 0.2x SSC/0.1% SDS at 65 °C for high  
25 stringency.

In a further embodiment, hybridisation of a nucleic acid molecule  
to a variant may be determined or identified indirectly, e.g. using  
a nucleic acid amplification reaction, particularly the polymerase  
30 chain reaction (PCR). PCR requires the use of two primers to  
specifically amplify target nucleic acid, so preferably two nucleic  
acid molecules with sequences characteristic of HQT are employed.  
Using RACE PCR, only one such primer may be needed (see "PCR  
protocols; A Guide to Methods and Applications", Eds. Innis et al,  
35 Academic Press, New York, (1990)).

Thus a method involving use of PCR in obtaining nucleic acid according to the present invention may include:

5 (a) providing a preparation of nucleic acid, e.g. from a plant cell,

10 (b) providing a pair of nucleic acid molecule primers for PCR, at least one of said primers being a primer according to the present invention as discussed above,

(c) contacting nucleic acid in said preparation with said primers under conditions for performance of PCR,

15 (d) performing PCR and determining the presence or absence of an amplified PCR product.

The presence of an amplified PCR product may indicate identification of a variant.

20 In all cases above, if need be, clones or fragments identified in the search may be extended. For instance if it is suspected that they are incomplete, the original DNA source (e.g. a clone library, mRNA preparation etc.) can be revisited to isolate missing portions e.g. using sequences, probes or primers based on that portion which  
25 has already been obtained to identify other clones containing overlapping sequence. As used herein, unless the context demands otherwise, the term HQT is intended to cover any of the nucleic acids of the invention described above, including functional variants.

30 The methods described above may also be used to determine the presence of one of the nucleotide sequences of the present invention within the genetic context of an individual plant, optionally a transgenic plant such as may be produced as described  
35 in more detail below. This may be useful in plant breeding programmes e.g. to directly select plants containing alleles which are responsible for desirable traits in that plant species, either

in parent plants or in progeny (e.g hybrids, F1, F2 etc.). Thus use of markers which can be designed by those skilled in the art on the basis of the nucleotide sequence information disclosed herein, for selection of a gene encoding a polypeptide with HQT activity, forms one part of the present invention.

As used hereinafter, all such HQT-related nucleotide sequences discussed or obtainable as described above will be referred to as "HQT nucleotide sequences" or "HQT nucleic acids" unless context demands otherwise.

In a further aspect of the present invention, HQT nucleotide sequences are in the form of a recombinant and preferably replicable vector.

'Vector' is defined to include, inter alia, any plasmid, cosmid, phage or Agrobacterium binary vector in double or single stranded linear or circular form which may or may not be self transmissible or mobilizable, and which can transform a prokaryotic or eukaryotic host either by integration into the cellular genome or exist extrachromosomally (e.g. autonomous replicating plasmid with an origin of replication).

Generally speaking, those skilled in the art are well able to construct vectors and design protocols for recombinant gene expression. Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. For further details see, for example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al, 1989, Cold Spring Harbor Laboratory Press or Current Protocols in Molecular Biology, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992.

Specifically included are shuttle vectors by which is meant a DNA vehicle capable, naturally or by design, of replication in two

different host organisms, which may be selected from actinomycetes and related species, bacteria and eucaryotic (e.g. higher plant, mammalian, yeast or fungal cells).

- 5 A vector including nucleic acid according to the present invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the genome.
- 10 Preferably the nucleic acid in the vector is under the control of, and operably linked to, an appropriate promoter or other regulatory elements for transcription in a host cell such as a microbial, e.g. bacterial, or plant cell. The vector may be a bi-functional expression vector which functions in multiple hosts. In the case
- 15 of genomic DNA, this may contain its own promoter or other regulatory elements and in the case of cDNA this may be under the control of an appropriate promoter or other regulatory elements for expression in the host cell.
- 20 By "promoter" is meant a sequence of nucleotides from which transcription may be initiated of DNA operably linked downstream (i.e. in the 3' direction on the sense strand of double-stranded DNA).
- 25 "Operably linked" means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter.
- 30 In a preferred embodiment, the promoter is an inducible promoter.

The term "inducible" as applied to a promoter is well understood by those skilled in the art. In essence, expression under the control of an inducible promoter is "switched on" or increased in response

35 to an applied stimulus. The nature of the stimulus varies between promoters. Some inducible promoters cause little or undetectable levels of expression (or no expression) in the absence of the

appropriate stimulus. Other inducible promoters cause detectable constitutive expression in the absence of the stimulus. Whatever the level of expression is in the absence of the stimulus, expression from any inducible promoter is increased in the presence  
5 of the correct stimulus.

Thus this aspect of the invention provides a gene construct, preferably a replicable vector, comprising a promoter (optionally inducible) operably linked to a nucleotide sequence provided by the  
10 present invention, such as the HQT gene or a variant thereof.

Particularly of interest in the present context are nucleic acid constructs which operate as plant vectors. Specific procedures and vectors previously used with wide success upon plants are described  
15 by Guerineau and Mullineaux (1993) (Plant transformation and expression vectors. In: Plant Molecular Biology Labfax (Croy RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148). Suitable vectors may include plant viral-derived vectors (see e.g. EP-A-194809).

20 Suitable promoters which operate in plants include the Cauliflower Mosaic Virus 35S (CaMV 35S). Other examples are disclosed at pg 120 of Lindsey & Jones (1989) 'Plant Biotechnology in Agriculture' Pub. OU Press, Milton Keynes, UK. The promoter may be selected to  
25 include one or more sequence motifs or elements conferring developmental and/or tissue-specific regulatory control of expression. Inducible plant promoters include the ethanol induced promoter of Caddick et al (1998) Nature Biotechnology 16: 177-180.

30 If desired, selectable genetic markers may be included in the construct, such as those that confer selectable phenotypes such as resistance to antibiotics or herbicides (e.g. kanamycin, hygromycin, phosphinotricin, chlorsulfuron, methotrexate, gentamycin, spectinomycin, imidazolinones and glyphosate).

35

The present invention also provides methods comprising introduction of a construct of the invention into a plant cell or a microbial

cell and/or induction of expression of a construct within such cell, by application of a suitable stimulus e.g. an effective exogenous inducer.

5 The invention further encompasses a host cell transformed with nucleic acid or a vector according to the present invention (e.g. comprising an HQT nucleotide sequence) especially a plant or a microbial cell. In the transgenic plant cell (i.e. transgenic for the nucleic acid in question) the transgene may be on an extra-  
10 genomic vector or incorporated, preferably stably, into the genome. There may be more than one heterologous nucleotide sequence per haploid genome.

The term "heterologous" is used broadly in this aspect to indicate  
15 that the gene/sequence of nucleotides in question (e.g. encoding HQT) have been introduced into said cells of the plant or an ancestor thereof, using genetic engineering, i.e. by human intervention. A heterologous gene may replace an endogenous equivalent gene, i.e. one which normally performs the same or a  
20 similar function, or the inserted sequence may be additional to the endogenous gene or other sequence. Nucleic acid heterologous to a plant cell may be non-naturally occurring in cells of that type, variety or species. Thus the heterologous nucleic acid may comprise a coding sequence of or derived from a particular type of  
25 plant cell or species or variety of plant, placed within the context of a plant cell of a different type or species or variety of plant. A further possibility is for a nucleic acid sequence to be placed within a cell in which it or a homologue is found naturally, but wherein the nucleic acid sequence is linked and/or  
30 adjacent to nucleic acid which does not occur naturally within the cell, or cells of that type or species or variety of plant, such as operably linked to one or more regulatory sequences, such as a promoter sequence, for control of expression.

35 Thus a further aspect of the present invention provides a method of transforming a host cell involving introduction of a construct as described above into a host cell and causing or allowing

recombination between the vector and the host cell genome to introduce a nucleic acid according to the present invention into the genome. Preferably, the host cell will be a plant cell.

- 5 The host cell (e.g. plant cell) is preferably transformed by the construct, which is to say that the construct becomes established within the cell, altering one or more of the cell's characteristics.
- 10 Nucleic acid can be introduced into plant cells using any suitable technology, such as a disarmed Ti-plasmid vector carried by Agrobacterium exploiting its natural gene transfer ability (EP-A-270355, EP-A-0116718, NAR 12(22) 8711 - 87215 1984), particle or microprojectile bombardment (US 5100792, EP-A-444882, EP-A-434616)
- 15 microinjection (WO 92/09696, WO 94/00583, EP 331083, EP 175966, Green et al. (1987) Plant Tissue and Cell Culture, Academic Press), electroporation (EP 290395, WO 8706614 Gelvin Debeyser) other forms of direct DNA uptake (DE 4005152, WO 9012096, US 4684611), liposome mediated DNA uptake (e.g. Freeman et al. Plant Cell Physiol. 29:
- 20 1353 (1984)), or the vortexing method (e.g. Kindle, PNAS U.S.A. 87: 1228 (1990d) Physical methods for the transformation of plant cells are reviewed in Oard, 1991, Biotech. Adv. 9: 1-11.

Agrobacterium transformation is widely used by those skilled in the art to transform dicotyledonous species.

- Recently, there has also been substantial progress towards the routine production of stable, fertile transgenic plants in almost all economically relevant monocot plants (see e.g. Hiei et al. (1994) The Plant Journal 6, 271-282)). Microprojectile bombardment, electroporation and direct DNA uptake are preferred where Agrobacterium alone is inefficient or ineffective.
- Alternatively, a combination of different techniques may be employed to enhance the efficiency of the transformation process,
- 35 eg bombardment with Agrobacterium coated microparticles (EP-A-486234) or microprojectile bombardment to induce wounding followed by co-cultivation with Agrobacterium (EP-A-486233).

- The particular choice of a transformation technology will be determined by its efficiency to transform certain plant species as well as the experience and preference of the person practising the invention with a particular methodology of choice. It will be apparent to the skilled person that the particular choice of a transformation system to introduce nucleic acid into plant cells is not essential to or a limitation of the invention.
- 10 Generally speaking, following transformation, a plant may be regenerated, e.g. from single cells, callus tissue or leaf discs, as is standard in the art. Almost any plant can be entirely regenerated from cells, tissues and organs of the plant. Available techniques are reviewed in Vasil et al., Cell Culture and Somatic
- 15 Cell Genetics of Plants, Vol I, II and III, Laboratory Procedures and Their Applications, Academic Press, 1984, and Weissbach and Weissbach, Methods for Plant Molecular Biology, Academic Press, 1989.
- 20 The generation of fertile transgenic plants has been achieved in the cereals rice, maize, wheat, oat, and barley (reviewed in Shimamoto, K. (1994) Current Opinion in Biotechnology 5, 158-162.; Vasil, et al. (1992) Bio/Technology 10, 667-674; Vain et al., 1995, Biotechnology Advances 13 (4): 653-671; Vasil, 1996, Nature
- 25 Biotechnology 14 page 702).

Plants which include a plant cell according to the invention are also provided.

- 30 In addition to the regenerated plant, the present invention embraces all of the following: a clone of such a plant, seed, selfed or hybrid progeny and descendants (e.g. F1 and F2 descendants).
- 35 A plant according to the present invention may be one which does not breed true in one or more properties. Plant varieties per se



may be excluded, particularly registrable plant varieties according to Plant Breeders' Rights.

The invention also provides a plant propagule from such plants,  
5 that is any part which may be used in reproduction or propagation, sexual or asexual, including cuttings, seed and so on. It also provides any part of these plants e.g. edible leaves which includes the plant cells or heterologous DNA described above.

10 The invention further provides a method of influencing or affecting chlorogenic acid synthesis in a plant, the method including the step of causing or allowing expression of a heterologous HQT nucleic acid sequence as discussed above within the cells of the plant.

15 The step may be preceded by the earlier step of introduction of the nucleic acid into a cell of the plant or an ancestor thereof.

In a preferred embodiment of the invention, plants may be stably  
20 transformed with a vector containing a HQT nucleotide sequence to increase chlorogenic acid synthesis within the plant's cells. Alternatively, transient expression of HQT in a plant may be achieved by, for example, infiltration of plant tissues with *Agrobacterium tumefaciens* containing a vector comprising a HQT  
25 nucleotide sequence. Non-limiting demonstration of both transient and stable expression is given below. For example, the inventors have stably transformed tobacco and tomato plants with a binary vector containing the cDNA of HQT from tobacco and tomato under the control of the double 35S promoter (Example 8). They have also  
30 demonstrated transient expression of HQT and concomitant increase in chlorogenic acid production in leaves of *Nicotiana benthamiana*, as set forth in Example 9.

Increasing chlorogenic acid production in stable transformed  
35 plants, preferably tobacco and tomato, may improve their antioxidant content, which is of significance for plants and also for nutrition. Plants overexpressing HQT may be produced and

analysed under different environmental conditions, in order to address the antioxidant function of HQT in tomato and tobacco. Other traits which may be influenced include pathogen resistance and abiotic stress.

5

The foregoing discussion has been generally concerned with uses of the nucleic acids of the present invention for production of functional polypeptides, thereby increasing the amount of chlorogenic acid produced and hence the level of chlorogenic acid activity.

10

However the information disclosed herein may also be used to reduce chlorogenic acid activity by down-regulation of HQT in cells in which it is desired to do so, thereby having the opposite effect.

15

This may be desirable, for example, for altering texture or palatability of a host plant.

Down-regulation of HQT expression may, for instance, be achieved using anti-sense technology.

20

In one embodiment, antisense technology may be used to down-regulate HQT expression to inhibit flux to chlorogenic acid so that there will be an increase in ferulic acid which, if cross-linked in the cell walls, will give rise to firmer, crunchier, better-textured plant tissues.

25

As with plants overexpressing HQT, plants in which HQT expression is downregulated may be produced and analysed under different environmental conditions to investigate the antioxidant function of HQT in plants.

30

In using anti-sense genes or partial gene sequences to down-regulate gene expression, a nucleotide sequence is placed under the control of a promoter in a "reverse orientation" such that transcription yields RNA which is complementary to normal mRNA transcribed from the "sense" strand of the target gene. See, for example, Rothstein et al, 1987; Smith et al, (1988) Nature 334, 724-

35

726; Zhang et al, (1992) The Plant Cell 4, 1575-1588, English et al., (1996) The Plant Cell 8, 179-188. Antisense technology is also reviewed in Bourque, (1995), Plant Science 105, 125-149, and Flavell, (1994) PNAS USA 91, 3490-3496.

5

Thus, as described above, a nucleotide sequence which is complementary to any of those coding sequences disclosed above forms a further aspect of the present invention.

- 10 An alternative to anti-sense is to use a copy of all or part of the target gene inserted in the sense orientation, to achieve reduction in expression of the target gene by co-suppression. See, for example, van der Krol et al., (1990) The Plant Cell 2, 291-299; Napoli et al., (1990) The Plant Cell 2, 279-289; Zhang et al.,
- 15 (1992) The Plant Cell 4, 1575-1588, and US-A-5,231,020. Further refinements of the co-suppression technology may be found in WO95/34668 (Biosource); Angell & Baulcombe (1997) The EMBO Journal 16,12:3675-3684; and Voinnet & Baulcombe (1997) Nature 389: pg 553.
- 20 Another alternative to antisense is 'gene silencing' by RNA interference (RNAi), in which double stranded RNA (dsRNA) is used to block gene expression. The dsRNA is cleaved into fragments known as interfering RNAs (iRNAs), which direct the degradation of mRNAs with the same sequence as the iRNAs. Hence, dsRNA comprising
- 25 the sequence of a target gene can be used to prevent expression of that gene.

For gene silencing of HQT, the inventors have cloned parts of the cDNA of HQT in an iRNA binary vector using the GATEWAY™ system

30 available from Invitrogen (see Example 7) for use in stable and transient transformation of tobacco and tomato plants as described herein.

Further options for down regulation of gene expression include the

35 use of ribozymes, e.g. hammerhead ribozymes, which can catalyse the site-specific cleavage of RNA, such as mRNA (see e.g. Jaeger (1997) 'The new world of ribozymes' Curr Opin Struct Biol 7:324-335, or

Gibson & Shillitoe (1997)'Ribozymes: their functions and strategies for their use' Mol Biotechnol 7: 242-251.)

5 The complete sequence corresponding to the coding sequence (in reverse orientation for anti-sense) need not be used. For example fragments of sufficient length may be used. It is a routine matter for the person skilled in the art to screen fragments of various sizes and from various parts of the coding sequence to optimise the level of anti-sense inhibition. It may be advantageous to include  
10 the initiating methionine ATG codon, and perhaps one or more nucleotides upstream of the initiating codon. A further possibility is to target a conserved sequence of a gene, e.g. a sequence that is characteristic of one or more genes, such as a regulatory sequence.

15 The sequence employed may be about 500 nucleotides or less, possibly about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, or about 100 nucleotides. It may be possible to use oligonucleotides of much shorter lengths, 14-23 nucleotides,  
20 although longer fragments, and generally even longer than about 500 nucleotides are preferable where possible, such as longer than about 600 nucleotides, than about 700 nucleotides, than about 800 nucleotides, than about 1000 nucleotides or more.

25 It may be preferable that there is complete sequence identity in the sequence used for down-regulation of expression of a target sequence, and the target sequence, although total complementarity or similarity of sequence is not essential. One or more nucleotides may differ in the sequence used from the target gene.  
30 Thus, a sequence employed in a down-regulation of gene expression in accordance with the present invention may be a wild-type sequence (e.g. gene) selected from those available, or a variant of such a sequence.

35 The sequence need not include an open reading frame or specify an RNA that would be translatable. It may be preferred for there to be sufficient homology for the respective anti-sense and sense RNA

molecules to hybridise. There may be down regulation of gene expression even where there is about 5%, 10%, 15% or 20% or more mismatch between the sequence used and the target gene.

Effectively, the homology should be sufficient for the down-  
5 regulation of gene expression to take place.

Thus the present invention further provides the use of the nucleotide sequence of Fig 7, or its complement, or a variant of either for down-regulation of gene expression, particularly down-  
10 regulation of expression of the HQT gene or a homologue thereof, preferably in order to influence the levels of chlorogenic acid in a plant.

Anti-sense or sense regulation may itself be regulated by employing  
15 an inducible promoter in an appropriate construct.

The present invention also encompasses the expression product of any of the coding (sense) nucleic acid sequences disclosed above, and methods of making the expression product by expression from  
20 encoding nucleic acid therefore under suitable conditions, which may be in suitable host cells.

Following expression, the product may be isolated from the expression system (e.g. microbial) and may be used as desired.  
25

Preferably, the product will have the sequence of one of the polypeptides shown in Figure 3.

Purified HQT or variant protein, produced recombinantly by  
30 expression from encoding nucleic acid therefor, may be used to raise antibodies employing techniques which are standard in the art. Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from  
35 immunised animals using any of a variety of techniques known in the art, and might be screened, preferably using binding of antibody to antigen of interest. For instance, Western blotting techniques or

- immunoprecipitation may be used (Armitage et al, 1992, Nature 357: 80-82). Antibodies may be polyclonal or monoclonal. As an alternative or supplement to immunising a mammal, antibodies with appropriate binding specificity may be obtained from a
- 5 recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see W092/01047.
- 10 Specific binding members such as antibodies and polypeptides including antigen binding domains of antibodies that bind and are preferably specific for HQT or variant or derivative thereof represent further aspects of the present invention, as do their use and methods which employ them.
- 15 All documents cited herein are hereby incorporated by reference inasmuch as is required for the skilled person to carry out the invention.
- 20 The invention will now be further described with reference to the following non-limiting Figures and Examples. Other embodiments of the invention will occur to those skilled in the art in the light of these.

## FIGURES

Figure 1 describes the purification of HQT from *Nicotiana tabacum*.

5

Figure 2 shows how the tomato HQT sequence was assembled from tomato EST clones. Peptide sequences obtained from Q-TOF analysis of the purified HQT protein were identified as parts of the tobacco EST clone AB 0015550 using Blast search analysis. Proceeding from this EST clone, homologous and overlapping tomato EST clones were found and the full-length cDNA of HQT from tomato assembled.

10

Figure 3 is an alignment of HQT from tobacco and tomato using MultiAlin (Corpet), 1988). Black background represents highly conserved regions of identical or similar amino acid residues, while they grey background indicates less conserved regions.

15

The consensus sequence of the CoA-transferase family ('cons') is shown below the HQT sequences. The conserved amino acid motif which is involved in the interaction with the CoA moiety of the substrate is boxed.

20

Figure 4 is a phylogenetic tree of HQT proteins from tomato and tobacco. Tomato and tobacco HQT and the related sweet potato protein are shown at the far right. Other branches of the tree represent different proteins of the COA transferase family. The proteins represented are, in clockwise order from Hsrp201:

25

- Hypersensitive response protein 201 from *Nicotiana tabacum*
- 30 - Anthranilate N-hydroxycinnamoyl/benzoyl transferase T10711/T10717 from *Dianthus caryophyllus*
- Tomato HQT from *Lycopersicon esculentum*
- Tobacco HQT from *Nicotiana tabacum*
- N-hydroxycinnamoyl/benzoyl transferase from *Ipomoea batatas*
- 35 - Anthranilate N-hydroxycinnamoyl/benzoyl transferase from *Arabidopsis thaliana*
- N-hydroxycinnamoyl/benzoyl transferase *Arabidopsis thaliana*

- Putative anthranilate N-hydroxycinnamoyl/benzoyl transferase from *Arabidopsis thaliana*

Figure 5 shows the expression of hsr201 and tomHQT in *Escherischia coli*.

Panel (a) shows Western blot analysis of crude protein extracts from E.coli expressing hsr201 or tomHQT compared to extracts from E. coli transformed with control plasmid (pSTAG). The protein was detected using S-protein alkaline phosphates conjugate.

Panel (b) shows an HQT enzyme assay with crude extracts from E. coli expressing hrs201 or tom HQT. The reaction was initiated by adding the substrate quinic acid and the enzyme activity was measured spectrophotometrically as decrease of the amount of caffeoyl-CoA.

Figure 6 demonstrates transient expression of HQT from tomato and tobacco in leaves of benthamiana.

Panel (a) shows expression of GFP in *N. benthamiana* leaves. Leaves were infiltrated with *Agrobacterium tumefaciens* C58C1 transformed with the plasmid pGFP, which contains the cDNA encoding GFP under control of the 35S promoter, along with bacteria transformed with either the plasmid p19 which carries a cDNA encoding a gene-silencing protein or the control plasmid pBIN19. The expression of GFP was monitored under UV light.

Panel (b) shows the amount of chlorogenic acid detected in leaves infiltrated with *Agrobacterium tumefaciens* transformed with pGFP, the plasmid pTom which carries the tomato HQT cDNA, or the plasmid pTob which carries the tobacco HQT cDNA, along with bacteria transformed with either p19 or pBIN19 as indicated. The amount of chlorogenic acid in the infiltrated leaf material was measured by HPLC analysis after 4 days.

Figure 7 shows the cDNA nucleotide sequences of tomHQT (7a) and tobHQT (7b). The transcriptional start and stop codons are indicated in bold and the coding sequence is underlined.



SEQUENCES

- SEQ ID NO 1 is the amino acid sequence of tomato HQT shown in  
5 Figure 3
- SEQ ID NO 2 is the amino acid sequence of tobacco HQT shown in  
Figure 3
- SEQ ID NO 3 is the nucleotide sequence of tobacco HQT shown in  
Figure 7b
- 10 SEQ ID NO 4 is the nucleotide sequence of tomato HQT shown IN  
Figure 7a

EXAMPLESExample 1 - Enzyme extraction and purification

5

200 g frozen leaf material from *Nicotiana tabacum* Samsun NN was ground to a homogenous powder in liquid nitrogen using mortar and pestle. All further purification steps were carried out at 4°C.

- 10 The powder was then transferred to 600 ml extraction buffer (0.1 M K-Pi buffer containing 1.8% PVPP, 1% PEG 6000, 1.2% ascorbic acid, 20  $\mu\text{g ml}^{-1}$   $\alpha^2$ -macroglobulin and 5 mM DTT) and stirred until a homogenous solution was obtained. After shaking for 20 min the slurry was passed through a double layer of Miracloth and the
- 15 filtrate was centrifuged at 25,000g for 30 min. The supernatant was stirred for 20 min with 10% Dowex 1x2 100-200 which had previously been equilibrated with 0.1 M K-Pi buffer containing 1.2% ascorbic acid, 1% PEG 6000 and 5mM DTT. After centrifugation at 13,000g for 10 min protamine sulphate (0.1 mg per 1mg protein) was added to the
- 20 supernatant. The slurry was then stirred for 20 min and the precipitated protein was collected by centrifugation (30 min at 25,000g).

- The supernatant was made up to 30% satn with finely ground  $(\text{NH}_4)_2\text{SO}_4$  and stirred for 30 min. The resultant precipitated protein was then removed by centrifugation for 30 min at 25,000g and the supernatant was raised to 80% satn.

- After stirring for 30 min the precipitated protein was pelleted by centrifugation at 25,000g for 1 h and the pellet was dissolved in
- 30 100 ml 10 mM Tris-HCl buffer pH 7.5 containing 5 mM DTT. The protein solution was desalted by dialysis against 10 mM Tris-HCl buffer pH 7.5 overnight.

- The protein extract was chromatographed on a DEAE-sepharose (Pharmacia) column (26 cm x 2.6 cm), which had been equilibrated
- 35 with 10 mM Tris-HCl buffer pH 7.5. A gradient of 0-1M KCl in 10 mM Tris-HCl pH 7.5 was applied at a flow rate of 1 ml min<sup>-1</sup> and 10 ml fractions were collected. The fraction with the highest enzyme

activity was dialysed against 10 mM Tris-HCl pH7.5 for 4 h and then applied to a MonoQ (Pharmacia) column (1 ml), pre-equilibrated in 10 mM Tris-HCl pH 7.5. The proteins were eluted by applying a gradient of 0-600 mM KCl in 10 mM Tris-HCl pH7.5 at a flow rate of 0.5 ml min<sup>-1</sup> and 1 ml samples were collected. The two fractions with the highest enzyme activity were pooled and diluted 1:10 with 10 mM Tris-HCl pH 7.5 to reduce the salt concentration. After application onto a MonoQ column the proteins were eluted using a gradient of 0-300 mM KCl in 10 mM Tris-HCl at a flow rate of 0.5 ml min<sup>-1</sup> and 1 ml fractions were collected. The fraction with the highest enzyme activity was diluted 1:10 with 10 mM Tris-HCl pH 7.5 containing 1.7 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>. The protein extract was then chromatographed on a phenylsucrose (Pharmacia) column (1 ml), pre-equilibrated in 10 mM Tris-HCl pH 7.5/ 1.7 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, using a 0-100 mM Tris-HCl pH 7.5 gradient at a flow rate of 0.25 ml min<sup>-1</sup> and 1 ml fractions were collected. The fraction with the highest enzyme activity was concentrated and desalted for polyacrylamide gel electrophoresis (SDS-PAGE) using Microcon YM-10 centrifugal filter devices (Millipore) pH 7.5.

SDS-PAGE was carried out using Tris-glycine pH 8.5 as the buffer system with a 10 % acrylamide gel (LAEMMLI, 1970). The 10-fold concentrated enzyme extract was applied and the electrophoresis was carried out at 20 mA. The proteins were visualised using Coomassie Blue. The band containing the putative enzyme was cut out and used for Q-TOF analysis (IFR and JIC Joint Proteomics Facility).

#### Example 2 - Enzyme activity

The enzyme activity was determined by spectrophotometry at 30°C. The reaction mixture contained in a total volume of 1 ml: 100 mM Na-Pi buffer pH 7.0, 1 mM EDTA, 16.8 µM caffeoyl CoA and 10-50 µl protein extract. After initiation of the reaction by addition of 2 mM quinic acid the change of caffeoyl CoA into chlorogenic acid could be determined by measuring the rate of decrease in absorbance at 346 nm per minute over a period of 5-10 min. The extinction

coefficient for caffeoyl CoA is  $1.8 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$  (ZENK et al., 1980).

The synthesis of caffeoyl CoA was carried out as described previously (SEMLER et al., 1987).

5

Example 3 - Characterisation of HQT enzyme reaction product:  
chlorogenic acid

10 The reaction mixture was acidified to pH 2.0 with HCl and then  
extracted twice with 5 ml ethylacetate. After evaporation under  
vacuum at 40°C the pellet was dissolved in 200 µl 50 % methanol and  
injected into the HPLC apparatus. The HPLC analysis was carried out  
as previously described (WALDRON et al., 1996). The reaction product  
15 acid (Sigma).

Example 4 - Isolation of full-length cDNA of HQT by RT-PCR and 3'  
RACE

20 To isolate the full-length cDNA of HQT from tomato RT-PCR was  
carried out using the oligonucleotide B26: 5'-  
GACTCGAGTCGACATCGA(dT)17-3' for the RT reaction (FROHMAN et al.,  
1988), and the oligonucleotides EST tom U: 5'-  
CCATGGGAAGTGAAAAATGATGAAAA TTAATATC-3' (corresponding to  
25 nucleotides 128 to 160 of the tomato EST clone EST263250 and  
introducing a NcoI-site in front of the ATG) and EST tom L: 5'-  
GGATCCTCATAAATTCATATAAATATTTTCAAATA-3' (corresponding to  
nucleotides 472 to 500 of the tomato EST clone EST268373 and  
introducing a BamHI-site after the Stop-Codon) for the PCR  
30 reaction. The EST clones were identified by BLAST search using the  
peptide sequences obtained from Q-TOF analysis of the purified  
enzyme.

5 µg total RNA isolated from tomato leaves was used for the RT  
35 reaction which was carried out using the SUPERSCRIPT™ First-Strand  
Synthesis System according to the procedures provided by the  
manufacturer (GIBCO BRL).

The PCR reaction was conducted at 94°C for 40 sec, 55°C for 2 min, 72°C for 3 min in 40 cycles, and 72°C for 10 min. The reaction mixture contained 10 µl RT-reaction mixture (1:50 diluted), 1 x reaction buffer without MgSO<sub>4</sub>, 0.2 mM dNTPs, 0.25 µM EST tom U, 0.25 µM EST tom L, 5 % DMSO, 3 mM MgSO<sub>4</sub> and 2.5 U Pwo DNA-Polymerase (Roche) in a final volume of 100 µl.

The isolation of the cDNA of HQT from tobacco was conducted in two steps:

by 3'-RACE to amplify the C-terminal part of the cDNA using the oligonucleotide B26: 5'- GACTCGAGTCGACATCGA(dT)17-3' for the RT reaction, and the oligonucleotides EST tob inter: 5'- GAGCACGTCGAGTATCATCCTCCTC CATC-3' (corresponding to nucleotides 6 to 34 of the tobacco EST clone AB001550), the nested oligonucleotide EST tob inter2 U: 5'- CTAATTTTCATCATCAAAAAGCTTAGAATCCAC-3' (corresponding to nucleotides 36 to 66 of the tobacco EST clone AB001550 and introducing a Hind III-site) and B25: 5'- GACTCGAGTCGACATCG-3' for the PCR reaction;

by RT-PCR to amplify the N-terminal part of the cDNA using the oligonucleotide B26: 5'- GACTCGAGTCGACATCGA(dT)17-3' for the RT reaction, and the oligonucleotides EST tom U and EST tob inter2 L: 5'- GTGGATTCTAAGCTTTTTGATGATGAAATTAG-3' (corresponding to nucleotides 36 to 66 of the tobacco EST clone AB001550 and introducing a Hind III-site) for the PCR reaction.

5 µg total RNA isolated from tobacco leaves were used for the RT reaction which was carried out using the SUPERSRIPT™ First-Strand Synthesis System according to the manufacturers (GIBCO BRL) instructions.

The 3'-RACE-PCR reaction was conducted at 94°C for 40 sec, 55°C for 2 min, 72°C for 3 min in 40 cycles, and 72°C for 10 min. The reaction mixture contained 10 µl RT-reaction mixture (1:50 diluted), 1 x reaction buffer without MgSO<sub>4</sub>, 0.2 mM dNTPs, 0.25 µM EST tob inter, 0.25 µM B25, 2 mM MgSO<sub>4</sub> and 2.5 U Pwo DNA-Polymerase (Roche) in a final volume of 100 µl. The PCR products were diluted 500-fold and they were then used in a second PCR reaction, which

was carried out using the nested oligonucleotide EST tob inter2 and B25 under the some conditions.

To amplify the N-terminal part of the cDNA, a PCR reaction was conducted at 94°C for 40 sec, 45°C for 2 min, 72°C for 2 min in 10 cycles, followed by 30 cycles at 94°C for 40 sec, 55°C for 2 min, 72°C for 2 min, and finally at 72°C for 10 min. The reaction mixture contained 10 µl RT-reaction mixture (1:50 diluted), 1 x reaction buffer without MgSO<sub>4</sub>, 0.2 mM dNTPs, 0.25 µM EST tob inter2 L, 0.25 µM EST tom U, 3 mM MgSO<sub>4</sub>, 5 % DMSO and 2.5 U Pwo DNA-Polymerase (Roche) in a final volume of 100 µl.

After cloning of the PCR products into the plasmid pGEMOT easy, according to the procedures provided by the manufacturer (Promega), the products were sequenced using the ABI Prism™ Dye Terminator Cycle Sequencing Ready Reaction Kit according to the procedures provided by the manufacturer (Perkin Elmer).

The full-length cDNA of HQT from tobacco was obtained by assembling the two PCR products using the HindIII site that had been introduced within the sequence of the oligonucleotides used in the PCR reaction.

#### Example 5 Recombinant expression of HQT in *E. coli*

The full-length cDNA of HQT from tomato was subcloned in frame into the NcoI and BamHI-sites of the expression vector pSTAG under the control of the T7 RNA-Polymerase promoter. This strategy led to the introduction of a sequence encoding an S-TAG at the 5'-end of the cDNA. According to procedures provided by the manufacturer (Novagen), the expression and purification of the fusion protein was carried out using the S-TAG™ Thrombin Purification Kit. The enzyme activity of the purified protein was then analysed in HQT enzyme assays.

Example 6 - HPLC of soluble phenolics in *Nicotiana benthamiana* leaves

Soluble phenolics were extracted by vortexing 30 mg of frozen,  
 5 powdered leaf material in 300 µl of 70 % methanol. After addition  
 of 100 µl distilled water, the extract was vortexed again and then  
 spun for 10 sec at 13,000g to pellet the debris. The supernatant  
 was analysed by gradient HPLC (apparatus from Spectra Physics, San  
 Jose, CA) using a Columbus 5-µm C18 column (25 cm x 4.6 mm;  
 10 Phenomenex, Macclesfield, Cheshire, UK). Solvent A was 1 mM  
 trifluoroacetic acid, solvent B was acetonitrile, and the gradient  
 was run for 65 min at flow rate of 1 ml min<sup>-1</sup> with the following  
 concentrations: 0 min :100 % A, 0 % B; 50 min: 60 % A, 40 % B; 60  
 min: 30 % A, 70 % B; 65 min: 100 % A, 0 % B. The column eluant was  
 15 monitored using a Spectra Focus scanning detector (Spectra Physics).  
 A chlorogenic acid standard (Sigma) was used to quantify the amount  
 of chlorogenic acid in the leaf extracts.

Example 7 - Constructs for overexpression and gene silencing of HQT  
 20 in plants

For overexpression of HQT, the full-length cDNA of HQT from tomato  
 and tobacco was subcloned in frame into the NcoI and SmaI-sites of  
 the expression vector pJIT166 (available from JIC) under the  
 25 control of the double 35S-promoter. The expression cassette  
 containing the promoter, the cDNA and the CaMV terminator was then  
 cloned in the binary vector pBIN19 (BEVAN, 1984). The obtained  
 constructs pTom and pTob were used for transient and stable  
 transformation of tomato and tobacco plants in order to achieve  
 30 overexpression of HQT

For gene silencing of HQT, to obtain siRNA constructs 600 bp cDNA-  
 fragments of HQT from tobacco and tomato were amplified by PCR  
 using the oligonucleotides G-tom sil U: 5' -  
 35 GGGGACAAGTTTGTACAAAAAAGCAGGCTCAGATTACTCGTTTCAAGTGTGGC -3', G-tom  
 sil L: 5' - GGGGACCACTTTGTACAAGAAAGCTGGGTTGATAA ATCAGGTGT  
 AATTCGAGG - 3' (corresponding to the nucleotides 424 to 447 and 1020

to 1044 of the tomato cDNA clone) and G-tob sil U: 5' -  
 GGGGACAAGTTTGTACAAAAAAGCAGGCTCAAATGTGGTGGAGTTTCACTG - 3' , G-tob  
 sil L: 5' - GGGGACCACTTTGTACAAGAAAGCTGGGTCTGGGCACT AATTCGAGGTAATC  
 (corresponding to the nucleotides 438 to 460 and 1034 to 1056 of  
 5 the tobacco cDNA clone). The cloning of the PCR fragments into the  
 vector pDONR201 was carried out using the GATEWAY™ Cloning system,  
 according to the procedures provided by the manufacturers  
 (INVITROGEN). After sequencing the fragments were cloned in both  
 directions into the RNAi plasmid pFRN (kindly provided by M.  
 10 Denekamp), which contains attR recombination site in sense and  
 antisense orientation spaced by an intron to enable the formation  
 of double stranded RNA. The production of dsRNA is driven by the  
 35S promoter. The constructs pFRN-tom and pFRN-tob were used for  
 stable and transient transformation of tomato and tobacco plants.

15

#### Example 8 - Stable transformation of tobacco and tomato plants

The pBIN19-derivatives pTom and pTob, which contain the full-length  
 cDNA of HQT from tomato and tobacco under the control of the double  
 20 35S, and the iRNA constructs pFRN-tom and pFRN-tob were transferred  
 to *Agrobacterium tumefaciens* LBA 4404 (HOEKEMA et al., 1983). A  
 single, transformed colony was used to obtain a 50 ml overnight  
 culture. After being pelleted by centrifugation for 20 min at 4000g  
 the cells were resuspended in 50 ml MS medium and used for  
 25 transformation of leaf discs from *Nicotiana tabacum* var Samsun NN  
 (HORSCH et al., 1985) and of cotyledons from *Lycopersicon esculentum*  
 var MoneyMaker (FILLATI et al., 1987). Developing shoots were cut  
 and transferred onto MS medium containing 100 ug/ml Kanamycin and  
 500 ug/ml Cefotaxim (tobacco) or 200 ug/ml Augmentin (tomato) for  
 30 rooting.

#### Example 9 - Transient expression of HQT in leaves of tobacco plants

After the transfer of the overexpression constructs pTom and pTob,  
 35 and the iRNA constructs pFRNtom and pFRN-tob to *Agrobacterium*  
*tumefaciens* C58C1 (DEBLAERE et al., 1985) single colonies were used  
 for growing 50ml overnight cultures. Additional 50 ml overnight



cultures of *Agrobacterium tumefaciens* C58C1 containing expression constructs of the green fluorescent protein (pGFP) or the gene silencing

inhibitor protein 19 (p19; kindly provided by O. Vionnet) or the empty binary vectors pBIN19 and pFRN were also grown. The cells were precipitated by centrifugation at 4000g for 20 min and resuspended in 50 ml 10mM MgCl<sub>2</sub>. After addition of 50µl 100 mM acetosyringene the cells were incubated at room temperature overnight. To overexpress HQT similar amounts of the cultures

containing pGFP, pTom, pTob were mixed with the same volume of cultures containing either pBIN19 or p19 and each mixture was used to infiltrate three leaves of a *Nicotiana benthamiana* plant. After 4 days, when the expression of GFP could be monitored under UV light, the leaf material was collected and used for quantification of the chlorogenic acid content by HPLC analysis. For gene silencing the cultures containing pFRN-tom, pFRN-tob and pFRN were used to infiltrate three leaves of *Nicotiana benthamiana*. After 7 days the leaf material was collected and also analysed by HPLC to measure the chlorogenic acid content.

REFERENCES

- 5 BEVAN, M. (1984): Binary Agrobacterium vectors for plant transformation. Nucl. Acids Res. 12, 8711-8721
- BRAVO, L. (1998): Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. Nutrition Reviews 56, 317-333
- 10 CASTELLUCCIO, C., PAGANGA, G., MELIKIAN, N., BOLWELL, G.P., PRIDHAM, J., SAMPSON J. and RICE-EVANS, C. (1995): Antioxidant potential of intermediates in phenyl propanoid metabolism in higher plants. FEBS Lett. 368, 188-192
- CORPET, F. (1988): Multiple sequence alignment with hierarchical clustering. Nucleic Acids Research 16 10881-10890
- 15 DEBLAERE, R., BYTEBIER, B., DE-GREVE, H., DEBOECK, F., SCHELL, J., VAN-MONTAGU, M. and LEEMANS, J. (1985): Efficient octopine Ti plasmid-derived vectors for Agrobacterium-mediated gene transfer to plants. Nucl. Acids Res. 13, 4777-4778
- 20 DEL MORAL, R. (1972): On the variability of chlorogenic acid concentration. Oecologia 9, 289-300
- DIAZ, J., BARCELO, A.R. and DE CACERES, F.M. (1997): Changes in shikimate dehydrogenase and the end products of the shikimate pathway, chlorogenic acid, and lignins, during the early
- 25 development of seedlings of Capsicum annum. New Phytol. 136, 183-188
- DIXON, R.A. and PAIVA, N.L. (1995): Stress-induced phenylpropanoid metabolism. Plant Cell 7, 1085-1097
- FILLATI, J.J., KISER, I., ROSE, S. and COMAI, L. (1987): Efficient
- 30 transfer of a glyphosphate tolerance gene into tomato using a binary Agrobacterium tumefaciens vector. Bio/Technology 5, 726-730
- FROHMAN, M.A., DUSH, M.K. and MARTIN, G.R. (1988): Rapid production of full-length cDNAs from rare transcripts: Amplification using single gene-specific oligonucleotide primer. Proc. Natl. Acad. Sci.
- 35 USA 85, 8998-9002

- GRACE, S.C. and LOGAN, B.A. (2000): Energy dissipation and radical scavenging by the plant phenylpropanoid pathway. *Phil. Trans. R. Soc. Lond. B* 355, 1499-1510
- GRACE, S.C., LOGAN, B.A. and ADAMS, W.W. (1998): Seasonal differences  
5 in foliar content of chlorogenic acid, a phenylpropanoid antioxidant, in *Mahonia repens*. *Plant Cell Environ.* 21, 513-521
- HOEKEMA, A., HIRSCH, P.R., HOOYKAS, P.J.J. and SCHILPERPOORT, R.A. (1983): A binary plant vector strategy based on separation of the vir and T-region of the *Agrobacterium tumefaciens* Ti-plasmid.  
10 *Nature* 303, 179-180
- HORSCH, R.B., FRY, J.E., HOFFMANN, D., EICHHOLTZ, D., ROGERS, S.G. and FRALEY, R.T. (1985): A simple and general method for transferring genes into plants. *Science* 227, 1229-1231
- KONO, Y., KOBAYASHI, K., TAGAWA, S., ADACHI, K., UEDA, A., SAWA, Y. and  
15 SHIBATA, H. (1997): Antioxidant activity of polyphenolics in diets. Rate constants of reactions of chlorogenic acid and caffeic acid with reactive species of oxygen and nitrogen. *Biochim. Biophys. Acta* 1335, 335-342
- KUEHN, T., KOCH, K., HELLER, H. and WELLMANN, E. (1987): Chlorogenic  
20 acid biosynthesis: Characterization of a light-induced microsomal 5-O-(4-coumaroyl)-D-quinic acid/shikimate 3'-hydroxylase from carrot (*Daucus carota* L.) cell suspension cultures. *Arch. Biochem. Biophys.* 258, 226-232
- LAEMMLI, U.K. (1970): cleavage of structural proteins during the  
25 assembly of the head of bacteriophage T4. *Nature* 227, 680-685
- LOTFY, S., FLEURIET, A. and MACHEIX, J.J. (1992): Partial purification and characterization of hydroxycinnamoyl CoA:transferases from apple and date fruits. *Phytochem.* 31, 767-772
- LOTFY, S. (1995): Inactivation and kinetic characterization of  
30 hydroxycinnamoyl-CoA:hydroaromatic acid O-hydroxycinnamoyltransferases from *Cichorium endivia* and *Phoenix dactylifera*. *Plant Physiol. Biochem.* 33, 423-431
- MACHEIX, J.J., SAPI, J.C., and FLEURIET, A. (1991): Phenolic compounds and polyphenoloxidase in relation to browning in grapes  
35 and wines. *Crit. Rev. Food Sci. Nutr.* 30, 441-486
- RICE-EVANS, C.A., MILLER, N.J. and PAGANGA, G. (1997): Antioxidant properties of phenolic compounds. *Trends Plant Science* 2, 152-159

- RHODES, M.J.C. and WOOLTORTON, L.S.C. (1976): The enzymic conversion of hydroxycinnamic acids to p-coumaroylquinic and chlorogenic acids in tomato fruits. *Phytochem* 15, 947-951
- 5 RHODES, J.M. and WOOLTORTON, L.S.C. (1978): The biosynthesis of phenolic compounds in wounded plant storage tissues. In *Biochemistry of Wounded Plant Tissues*. Walter de Gruyter & Co., Berlin, 243-286
- 10 RHODES, M.J., WOOLTORTON, L.S. and LOURENCO, E.J. (1979): Purification and properties of hydroxycinnamoyl CoA quinate hydroxycinnamoyl transferase from potatoes. *Phytochem.* 18, 1125-1129
- SCHOCH, G., GOEPFERT, S., MORANT, M., HEHN, A., MEYER, D., ULLMANN, P. and WERCK-REICHHART (2001): CYP98A3 from *Arabidopsis thaliana* is a 3'-hydroxylase of phenolic esters, a missing link in the phenylpropanoid pathway. *J Biol. Chem.* 276, 36566-36574
- 15 SEMLER, U., SCHMIDTBERG, G. and GROSS, G.G. (1987): Synthesis of piperoyl coenzyme-A thioester. *Z NATURFORSCH* 42, 1070-1074
- STOECKIGT, J. and ZENK, M.H. (1974): Enzymatic synthesis of chlorogenic acid from caffeoyl coenzyme A and quinic acid. *FEBS Lett.* 42, 131-134
- 20 STRACK, D. (1997): Phenolic metabolism. In *Plant Biochemistry*, p387-417. Academic Press Ltd
- ULBRICH, B. and ZENK, M.H. (1979): Partial purification and properties of hydroxycinnamoyl-CoA:quinic acid hydroxycinnamoyl transferase from higher plants. *Phytochem.* 19, 1625-1629
- 25 VILLEGAS, R.J.A. and KOJIMA, M. (1986): Purification and characterization of hydroxycinnamoyl D-glucose quinate hydroxycinnamoyl transferase in root of sweet potato. *J Biol. Chem.* 261, 8729-8733
- 30 WALDRON, K.W., PARR A.J., NG A. and RALPH J. (1996): Cell wall esterified phenolic dimers: Identification and quantification by reverse phase high performance liquid chromatography and diode array detection. *PHYTOCHEMICAL ANALYSIS* 7, 305-312
- YAO, K., DE LUCA, V. and BRISSON, N. (1995): Creation of a metabolic sink for tryptophan alters the phenylpropanoid pathway and the susceptibility of potato to *Phytophthora infestans*. *Plant Cell* 7, 1787-1799

ZENK, M.H., ULBRICH, B., BUSSE, J. and STOECKIGT, J. (1980): Procedure for the enzymatic synthesis and isolation of cinnamoyl-CoA thiolesters using a bacterial system. Analytical Biochemistry 101, 182-187

Figure 1

	Total protein mg	Enzyme activity nkat	Yield %	Specific activity nkat mg <sup>-1</sup>	Purification -fold
Crude extract	1716	51		0.03	
Ammonium sulphate precipitation (30-80%)	890	155	300	0.17	6
DEAE column	10.7	50	98	4.69	158
MonoQ column 80%	1.8	18.6	36	10.23	344
MonoQ column 30%	0.96	6.6	12	6.87	231
Phenylsucrose	0.07	1.2	2.4	18.03	600

nkat = 1  $\mu$ mol caffeoyl-CoA s<sup>-1</sup>

Figure 2




Figure 3

1 60  
 COBHOT MCSRMMKIN IKESTLVKPS RPTPTKIMOE SNLDLIVGRI HLLTWYFYRI NCSSNFELSI  
 COBHOT MCSRMMKIN IKESTLVKPS RPTPTKIMOE SNLDLIVGRI HLLTWYFYRI NCSSNFELSI  
 cons MK IK L KPS PTP L SNLD I G FYK S  
 61 120  
 LKREALSNIWI WSYFDMAGRI EDEEGRIEI NCNCEGVLFV EAESDAIVDI FCDFTPSLEI  
 LKREALSNIWI WSYFDMAGRI EDEEGRIEI NCNCEGVLFV EAESDAIVDI FCDFTPSLEI  
 K LS I V YP ACRI R G KI CN EG FU KA SD D F D P L  
 121 180  
 RKLIVWDTS GDISTFPLII FQVTRKCCG VSLGGCVFHT LSGGLSSIHV LNTWEDLARE  
 RKLIVWDTS GDISTFPLII FQVTRKCCG VSLGGCVFHT LSGGLSSIHV LNTWEDLARE  
 L P V S T PL QVT EECG C V H DG S E IN V ARG  
 181 240  
 LSWATPPFII RTLLRAEDPI TSSFEHWYH PPPSLISSR SLESTSPKPS TTTMKFSSEI  
 LSWATPPFII RTLLRAEDPI TSSFEHWYH PPPSLISSR SLESTSPKPS TTTMKFSSEI  
 P D R LI R PP H KY P K S  
 241 300  
 QLGLIKSKSP HDGSTYELH SHWRECKCKE BMSDDQLTR LHWATDCESI LCPPLPEGYI  
 QLGLIKSKSP HDGSTYELH SHWRECKCKE BMSDDQLTR LHWATDCESI LCPPLPEGYI  
 L IK K E A VEC KA L L A RSE L PPLP GY  
 301 360  
 CNWVFCTET AKSSELIDBI LTNSEKRIHS ELSEMDNNY RSALDYELI PDLSALIRCI  
 CNWVFCTET AKSSELIDBI LTNSEKRIHS ELSEMDNNY RSALDYELI PDLSALIRCI  
 CN V EL P L A A K YI RS D R L G  
 361 420  
 TYPASPMINI WSOTRLPWHI SDFCGRPHI MCPACHIEG TWYIPSPNE KDMRLRLATC  
 TYPASPMINI WSOTRLPWHI SDFCGRPHI MCPACHIEG TWYIPSPNE KDMRLRLATC  
 SW R P DEGC P CP PS D VC  
 421 486  
 LDANENHLE KYLYER  
 LDGCHSLEF WYVVR  
 L K EK K



Figure 4




Figure 5




Figure 6




Figure 7a

ATG GGAAGTGAAA AAATGATGAA AATTAATATC AAAGAATCAA  
CACTAGTGAA ACCATCAAAA CCAACACCAA CAAAGAGAAT TTGGAGTTCT  
AATTTGGATT TAATTGTTGG AAGAATTCAT CTTTGGACTG TTTATTTTAA  
TAAACCAAAT GGATCTTCAA ATTTTTTTGA TAATAAAGTT ATTAAAGAAG  
CATTAAGTAA TGTTTTAGTT TCATTTTATC CAATGGCTGG AAGATTAGGT  
AGGGATGAAC AAGGTAGAAT TGAAGTTAAT TGTAATGGTG AAGGTGTTTT  
GTTTGTTGAG GCTGAAAGTG ATTCATGTGT TGATGATTTT GGTGATTTTA  
CACCATCTTT GGAAGTTAGA AAATCATTC CAAGTGTTGA AACCTCTGGA  
GATATCTCAA CTTTCCCACT AGTTATATTT CAGATTACTC GTTCAAGTG  
TGGCGGAGTC GCTCTGGTG GTGGAGTATT CCACACGTTA TCCGATGGTC  
TCTCATCCAT CCACTTCATC AACACGTGGT CGGACATCGC CCGTGGCCTC  
TCCGTCGCAG TCCCGCCGTT CATCGATCGG ACGTCCTCC GTGCAAGGGA  
CCCACCGACA TATTCTTTCG AGCACGTTGA GTACCATCCT cCACCTACCC  
TAAATCATC GAAAAATcGC GAGTCCAGTA CCaCGACCAT GTTGAAATtc  
TCGAGTGAAC AACTCGGGCT TcTTAAGTCC AAGTCCAAAA ATGAGGGTAG  
CACCTATGAA ATCCTCGCAG CCCATATTTG GCGATGCACG TGCAAGGCAC  
GTGGATTGCC AGAGGATCAA TTGACCAAAT TACACGTGGC CACCGACGGA  
AGGTCAAGGC TTTGCCCTCC CTTGCCACCG GGTACCTAG GAAACGTCGT  
GTTACGGCA ACCCAATAG CTAAATCATG CGAACTTCAA TCAGAGCCGT  
TGACAAATTC CGTCAAGAGA ATTCACAACG AGTTGATCAA AATGGACGAC  
AATTACCTAA GATCAGCACT GGATTACCTC GAATTACAAC CTGATTTATC  
AACCCTAATT CGGGGCCCGG CTTACTTTGC TAGCCCTAAC CTCAATATTA  
ATAGTTGGAC TAGGTTGCCT GTCCATGAGT GTGATTTTGG ATGGGGTAGG  
CCaATTCATA TGGGACCAGC TTGCATTTTA TATGAAGGGA CaATTTATAT  
TATACCAAGT CCAAATTCTA AAGATAGGAA CTTGCGTTTG GCTGTTTGTc  
TAGATGCTGG TCACATGTCA CTATTTGAAA AATATTTATA TGAATTATGA

Figure 7b

ATGGGAAG TGAAAAAATG ATGAAAATTA ATATCAAGGA ATCAACATTA  
GTAAAACCAT CAAAACCAAC ACCAACAAAA AGACTTTGGA GTTCTAACTT  
AGATTTAATA GTGGGAAGAA TTCATCTTTT AACAGTATAT TTCTATAAAC  
CAAATGGATC TTCAAATTC TTTGATTCAA AAATAATGAA AGAAGCATT  
AGTAATGTTT TGTTCATT TTACCCAATG GCTGGAAGAT TAGCTAGAGA  
TGAACAAGGA AGAATTGAGA TAAATTGTAA TGGAGAAGGA GTTTTATTTG  
TTGAAGCTGA AAGTGATGCT TTTGTTGATG ATTTTGGTGA TTTTACTCCA  
AGTTTGGAAC TTAGGAACT TATTCCTACT GTTGACACTT CTGGTGATAT  
TTCTACTTTC CCCCTCATCA TCTTTCAGGT TACTCGTTTC AAATGTGGTG  
GAGTTTCACT TGGTGGAGGA GTATTCCACA CTTTATCAGA TGGTCTCTCA  
TCAATTCAC TCAATCAACAC ATGGTCCGAT ATAGCCCGAG GCCTCTCCGT  
CGCCATCCCG CCGTTCATCG ACCGGACCCT CCTCCGTGCA CGGGACCCAC  
CAACATCGTC TTTCGAGCAC GTCGAGTATC ATCCTCCTCC ATCTCTAATT  
TCATCATCAA AAAGCTTAGA ATCCACTAGC CCAAAGCCTA GTACCACAAC  
CATGTTAAAA TTCTCTAGTG ACCAACTTGG GCTTCTAAAG TCCAAGTCCA  
AACATGATGG TAGCACTTAC GAAATCCTCG CGGCCCATAT TTGGCGTTGC  
ACGTGCAAGG CACGTGCACT GTCCGACGAT CAATTGACCA AATTACATGT  
GGCCACTGAT GGTAGGTCTA GGCTTTGCCC TCCTTTGCCA CCAGGTACT  
TAGGAAATGT TGTGTTTACA GGCACACCTA TGGCAAATC AAGTGAAC TT  
TTACAAGAAC CATTGACAAA TTCAGCCAAG AGAATTCATA GTGCATTATC  
AAAAATGGAT GaCAATTaCC TAAGATCAGC TCTCGATTAC CTCGAATTAC  
TGCCCCGATTT ATCGGCTTTA ATCCGTGGAC CGACGTACTT TGCTAGCCCT  
AATCTTAATA TTAATAGTTG GACTAGATTG CCTGTTTATG ATTCAGATTT  
TGGATGGGGA AGGCCAATTC ATATGGGACC AGCTTGCAAT TTATATGAAG  
GGACAGTTTA TATATTGCCA AGTCCaAATA GTAAAGATAG GAACTTGCGT  
TTGGCTGTTT GTTTAgATGC TGATCACATG CCaCTATTTG AgAAGtATTT

GIATGAATTT TGAGAGGTTG AAAAAAAAAAT CAAGAATGTT CCAACaCTTG  
AGAATTATcT TAGGTGTGGG TGGTTTTGGA TTAAGGCATT TTGTAaCTTG  
TTTTCTATTG TTTTTTTGGG GGGTCAGTTT GTTTTCAAAA AAAAAAAAAA  
AAAAAAAA

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**